| Name | Serum paraoxonase/arylesterase 2 | ||
| UniProt ID | PON2_HUMAN | ||
| Gene Name | PON2 | ||
| Gene ID | 5445 | ||
| Synonyms |
PON2
|
||
| Sequence |
MGRLVAVGLLGIALALLGERLLALRNRLKASREVESVDLPHCHLIKGIEAGSEDIDILPN
GLAFFSVGLKFPGLHSFAPDKPGGILMMDLKEEKPRARELRISRGFDLASFNPHGISTFI DNDDTVYLFVVNHPEFKNTVEIFKFEEAENSLLHLKTVKHELLPSVNDITAVGPAHFYAT NDHYFSDPFLKYLETYLNLHWANVVYYSPNEVKVVAEGFDSANGINISPDDKYIYVADIL AHEIHVLEKHTNMNLTQLKVLELDTLVDNLSIDPSSGDIWVGCHPNGQKLFVYDPNNPPS SEVLRIQNILSEKPTVTTVYANNGSVLQGSSVASVYDGKLLIGTLYHRALYCEL |
||
| Pathway Map | MAP LINK | ||
| KEGG ID | hsa5445 | ||
| Pfam | PF01731; PF03088; PF08450 | ||
| Pair Name | Gossypol, Zoledronic acid | |||
| Phytochemical | Gossypol | |||
| Drug | Zoledronic acid | |||
| Disease Info | [ICD-11: 2C82.0] | Prostate cancer | Investigative | |
| Regulate Info | Down-regulation | Serum paraoxonase/arylesterase 2 | Expression | |
| Result | GP significantly enhances the anti-tumor activity of ZA in hormone- and drug-resistant prostate cancer cells by targeting many pivotal apoptosis-related proteins. | |||
